MONCPT: A novel camptothecin that inhibits proliferation of human tumor cells in vitro and in vivo

Bo Yang,Qiaojun He,Lingling Fan,Peihua Luo,Lu Wei,C. Patrick Reynolds
IF: 11.2
2005-01-01
Cancer Research
Abstract:Proc Amer Assoc Cancer Res, Volume 46, 2005 2388 MONCPT belongs to a novel family of camptothecin analogs, the nitro-camptothecins, developed on the concept of toposiomerase I (Topo I) inhibition. Preclinical data reported here showed that MONCPT inhibited Topo I-mediated DNA relaxation in vitro. In cell growth assays, MONCPT was a very potent antiproliferative agent as shown by IC50 values of 11 various cancer cell lines ranged from 1.7×10-6 M to 2.2×10-10 M. MONCPT exhibited high efficiency in vivo in tumor xenograft studies using human androgen-independent prostate tumors PC3 and human non-small-cell lung cancer A549, and the tumor inhibition rates were 30 - 95% with a dose-dependent pattern (5 - 20 mg/kg). Flow cytometric analysis showed that MONCPT failed to trigger apoptosis, but induced a G2/M phase arrest in PC3 cells. Western blot assay demonstrated that MONCPT could decrease protein expression of CDK7, and the ED50 for the inhibition of angiogenesis for MONCPT was1.0 mg in the chorioallantoic membrane model, indicating that the cell cycle modulation and anti-angiogensis property of MONCPT might contribute to its high anti-cancer activity. Altogether, these data strongly supported the promising clinical development of MONCPT.
What problem does this paper attempt to address?